Covaxin is safe and will protect against mutants, says Bharat Biotech

The Drug Controller General of India (DCGI) had on Sunday granted restricted use approval “in clinical trial mode” to Covaxin “in the public interest”. However, the regulator did not say whether the approval had been granted on the basis of efficacy data. 

https://ift.tt/eA8V8J from https://ift.tt/3b7fZbE